Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
  • A01N47/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/14—Ectoparasiticides, e.g. scabicides

Definitions

• the present invention relates to a liquid pharmaceutical composition
• a liquid pharmaceutical composition comprising, as active principle, an N-phenylpyrazole derivative, benzyl alcohol and a suitably selected organic solvent, and the use of such a composition for the the preparation of a topical veterinary antiparasitic drug for the prevention and / or treatment of flea infestations in domestic animals, particularly dogs and cats.
• Pets are often infested with one or more parasites feeding on blood such as dog fleas, cat fleas, ticks, or scabies.
• Fleas are wingless insects, with laterally compressed bodies and highly developed legs, suitable for jumping. They are ectoparasites, sucking blood from mammals or birds. The 2000 listed species belong to the order of siphonaptera. Two species of fleas are commonly found in Europe; it is the cat flea (Ctenocephalides felis) and the dog flea (Ctenocephalid.es canis) that live in the fur of animals. The cat flea, the most common, is able to breed both on the cat and the dog. It can also attack humans and other pets, however the cat is the main cause of infestation when cats and dogs live in the same environment.
• Fleas have a complex life cycle with 4 distinct stages: egg, larva, nymph and adult. They mate in the first 8 to 48 hours after the acquisition by the host, after their first blood meal. Females start laying eggs 24 to 48 hours after this first blood meal. The adult flea usually lays on the animal. Eggs laid on the animal do not stay there and fall on the ground. In optimal conditions, the female can lay more than 25 eggs per day. She will lay hundreds of them all her life. After a few days, a worm-shaped, white, hairy larva, about 1.5 mm long, is born. The larva feeds on organic debris, larval remains and dry blood defecated by adults.
• the larval state lasts from 1 to 3 weeks, if the conditions are favorable (18 ° to 27 ° C and 70% of relative humidity). The larva then weaves a cocoon and pupates. Normally, the nymph evolves in 1 to 2 weeks but the transition to the adult state can be prolonged until 1 year, if the conditions are unfavorable.
• the adult flea small and black emerges from the cocoon when it detects vibrations, heat, higher concentration of carbon dioxide, which occurs during the passage of a cat, a dog ... or a man! She then jumps on the victim, immediately feeds on blood and grows rapidly, taking a lighter, reddish-brown color. The adult flea lives from 6 to 12 months. Without food, she can survive for up to 2 months.
• Flea bites cause itching in both animals and humans.
• the saliva of the flea secreted with each bite) can also, according to individuals, cause allergic reactions, immediate or delayed. These reactions result in various skin and itchy lesions.
• Flea Allergy Dermatitis (DAPP) is the most common cause of pruritus in dogs. In France, in adult dogs, it accounts for almost half of the pruriginous dermatoses.
• Fleas of the genus Ctenocephalides are also intermediate hosts of Dipylidium caninum, which is a parasitic worm of the small intestine of dogs and cats.
• the carnivore becomes infested by swallowing parasitic fleas. This infestation may cause anal pruritus, engorgement of anal sacs, and dermatitis of the perineal region. Therefore, it is sometimes advisable to worm regularly the animals in addition to the fight against fleas.
• ticks (Rhipicephalus sp., Ixodes sp.,
• Ticks can also release toxins with crippling, inflammatory, and sometimes life-threatening properties.
• the gall (Demodex sp., Sarcoptes sp., Otodectes sp., ...) is particularly difficult to fight because there are very few effective active ingredients. It requires frequent treatments.
• Infestations by these parasites especially fleas, therefore represent a major health problem for animals that are infested and require the availability of appropriate treatments.
• the treatment should not only have immediate efficacy (rapidity of action) but also prolonged efficacy over time (remanence) in order to avoid, on the one hand, repeated treatments and, on the other hand, any risk of infestation and / or reinfestation for an extended period.
• the flea in particular, must be eliminated before it reoccurs and begins to spawn.
• patent applications EP 0 295 117 and EP 0 352 944 describe a large family of N-phenylpyrazoles having a very wide spectrum of activity, including antiparasitic activities.
• N-phenylpyrazole derivatives and especially 5-amino-1- [2,6-dichloro-4- (trifluoromethyl) phenyl] -4- (trifluoromethylsulfinyl) -1H-pyrazole-3-carbonitrile (fipronil), are sometimes difficult to formulate because they do not do not always have sufficient solubility in the excipients conventionally used for the preparation of ready-to-use liquid pest control compositions.
• the active products against blood-sucking parasites can be in particular in the form of liquid compositions (pipettes) or cutaneous solutions for depot or "Spot-
• Another object of the invention is to provide effective compositions that do not require to wet the entire animal.
• the antiparasitic pharmaceutical composition of the invention provides an effective and prolonged activity in the treatment and protection of domestic animals in ready-to-use ready-to-use solution.
• the present invention relates to a liquid pharmaceutical composition, characterized in that it contains:
• said pharmaceutical composition is in particular intended to be administered in the cat or in the dog.
• prpril is preferably 1 to 20% (w / v), and still more preferably 5 to 15% (w / v).
• the benzyl alcohol represents from 5 to 40% (weight / volume), and even more preferably from 25 to 35% (weight / volume).
• organic solvent s
• the above-mentioned organic solvent (s) are used in the amounts necessary to adjust the pharmaceutical composition to the final volume required.
• the weight / volume percentage of the organic solvent or of the organic solvent mixture depends on the nature (and therefore the density) of the solvent or solvent mixture used.
• diethylene glycol monoethyl is most preferred.
• the pharmaceutical composition used according to the invention may also contain one or more excipients which may for example be selected from surfactants, thickeners, dyes, perfumes, antioxidants, among which may be mentioned by way of non-limiting example. limiting butylhydroxyanisole, butylhydroxytoluene, propyl gallate, ascorbyl palmitate, rosemary extracts and mixtures thereof.
• the antioxidant agent (s) preferably represent approximately 0.005 to 2% (weight / volume), and still more preferably approximately 0.01 to 0.1% ( weight / volume).
• the pharmaceutical composition may also comprise one or more additional antiparasitic active ingredients.
• acaricides such as amitraz or cymiazole
• the inhibitors of flea and tick development often referred to as "IGRs” for "Insect Grpwth Regulators” in English, such as pyriproxyfen and ethoxazole
• endoparasiticides such as avermectins and their derivatives such as ivermectin, abamectin, doramectin and moxydectin, milbemycins, as well as compounds active against sand flies and ectoparasites in domestic animals.
• Such combinations of actives may be useful for broadening the spectrum of action of the composition according to the present invention.
• the pharmaceutical composition according to the invention can easily be prepared by simply diluting the fipronil and optionally the active ingredient (s). additional antiparasitic agents in benzyl alcohol and the organic solvent (s) used.
• the pharmaceutical composition is preferably packaged in single dose pipettes.
• Another object of the present application is the use of a liquid pharmaceutical composition as described above for the preparation of a topical antiparasitic veterinary medicament for the prevention (protection) and / or treatment of flea infestations in pets, especially dogs or cats.
• said medicament is intended to be applied by direct application to the skin of the animal, at the level of the shoulder blades or on a dorsal line extending from the base of the tail up to the neck.
• the amount of drug to be administered may vary from about 0.3 to about 1.5 ml, preferably from about 0.5 ml in the cat and from about 0.3 to about 6.0 ml in the dog, depending on the weight of the the animal considered and the dosage.
• the volume to be applied according to the invention should preferably correspond to a unit dose of prolonil ranging from 0.3 to 60 mg per kg of body weight, and still more preferably from 5 to 15 mg per kg of body weight.
• said medicament is intended to administer a unit dose of fipronil ranging from 0.3 to 60 mg per kg of body weight, and still more preferably from 5 to 15 mg per kg of weight. body.
• the invention also comprises other arrangements which will become apparent from the description which follows, which refers to an example of the preparation of a pharmaceutical composition according to the invention, as well as to examples setting forth highlighting the effectiveness of said composition vis-à-vis the treatment of fleas in dogs and cats.
• EXAMPLE 1 ANTIPUT COMPOSITION
• the following anti-chip composition was prepared by simply dissolving the fipronil in the mixture of the other constituents of the composition:
• the dogs were kept indoors in an air-conditioned room, each dog being confined in a single enclosure of dimensions 1.9 mx 2.97 m without litter and no contact possible between the different dogs involved in the study.
• the identification number, group number and type of composition administered was noted outside each pen.
• the room temperature was maintained at about 20 ° C ⁇ 4 ° C.
• the dogs were subjected to an alternation of 12 hours of light and 12 hours of darkness.
• Composition A according to the invention was compared to Frontline® Spot-on dog product containing 10% (g / 100 ml) of fipronil and a mixture of excipients. It has been used as supplied by the manufacturer. d) Treatments
• Group 1 Treatment with composition A at a rate of 0.67 ml per dog for dogs weighing between 2 and 10 kg, and at a rate of 1.34 ml per dog for dogs weighing between 10 kg and 20 kg,
• Group 2 Treatment with Frontline® Spot-on dog at the rate of 0.67 ml dog for dogs weighing between 2 and 10 kg, and at 1.34 ml per dog for dogs weighing more than 10 kg and 20 kg,
• V C is the geometric mean of the number of live fleas counted on dogs in group 3 (control);
• - NP V T is the geometric mean of the number of live fleas counted on dogs in a group that received treatment (Group 1 or 2).
• a treatment is said to be effective if the percentage of efficiency is greater than or equal to 95%.
• the dogs were kept indoors in an air-conditioned room, each dog being confined in a single enclosure of dimensions 1.9 mx 2.97 m without litter and no contact possible between the different dogs involved in the study.
• the identification number, group number and type of composition administered was noted outside each pen.
• the temperature of the room was kept at around
• Composition A according to the invention was compared to Frontline® Spot-on dog product containing 10% (g / 100 ml) of fipronil and a mixture of excipients. It has been used as supplied by the manufacturer.
• Treatments Group 1 Treatment with Composition A at a rate of 0.067 ml per kg of body weight,
• Group 2 Treatment with Frontline® Spot-on dog at 0.067 ml per kg of body weight
• V C is the geometric mean of the number of live fleas counted on dogs in group 3 (control);
• - NP V T is the geometric mean of the number of live fleas counted on dogs in a group that received treatment (Group 1 or 2).
• a treatment is said to be effective if the percentage of efficiency is greater than or equal to 95%.
• the cats used in this study were European adult cats, male or female, aged 7 months to 2 years, weighing an average of 6.7 ⁇ 0.1 kg. All cats acclimated to living conditions for at least 9 days before the start of the study.
• the cats were kept indoors in an air-conditioned room, each cat being confined in individual cages.
• the identification number, group number and type of composition administered was noted on each cage.
• the temperature of the room was maintained at a temperature of about 23 ° C ⁇ 2 ° C with a relative humidity of 60 ⁇ 10%.
• Composition A according to the invention was compared to Frontline® Spot-on cat product containing 10% (g / 100 ml) of Fipronil and a mixture of excipients. It has been used as supplied by the manufacturer. d) Treatments
• Group 1 Treatment with composition A at a rate of 0.5 ml per cat, or 50 mg of fipronil per animal,
• Group 2 Treatment with the product Frontline® Spot-on cat at a rate of 0.5 ml per cat, or 50 mg of fipronil per animal,
• Group 3 Negative control: no treatment.
• the first infestation occurred the day before treatment (J -1).
• % efficiency 100 ⁇ (NP V C - NP V T) / NP V C in which: - NP V C is the geometric mean of the number of live fleas counted on cats in group 3 (control);
• - NP V T is the geometric mean of the number of live fleas counted on cats in a group that received treatment (Groups 1 or 2).
• a treatment is said to be effective if the percentage of efficiency is greater than or equal to 95%.
• composition A Local tolerance monitoring was performed at 1 hour, 6 hours, 24 hours and 48 hours after treatment. During these observations, some cosmetic changes at the site of application of the composition A were noted, including in particular wicking phenomena (hairs stuck with ear formation) and a greasy appearance at 1 o'clock and 6 hours after application. Some white deposits (white powder, crystals) at the end of the hairs were also observed at 24 hours and 48 hours after the application of the treatment. Nevertheless, no sign of local or general intolerance has been reported for composition A throughout the test.
• composition A according to the present invention The efficacy and the best remanence of the composition A according to the present invention are thus clearly demonstrated.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Plant Pathology (AREA)
• Environmental Sciences (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Dermatology (AREA)
• Dentistry (AREA)
• Agronomy & Crop Science (AREA)
• Pest Control & Pesticides (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Tropical Medicine & Parasitology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)

Priority Applications (7)

Applications Claiming Priority (1)

Publications (1)

Family

ID=41057552

Family Applications (1)

Country Status (5)

Cited By (5)

Families Citing this family (3)

Citations (1)

Family Cites Families (5)

• 2008
  • 2008-12-16 BR BRPI0823302A patent/BRPI0823302B1/pt active IP Right Grant
  • 2008-12-16 WO PCT/FR2008/001756 patent/WO2010070210A1/fr active Application Filing
  • 2008-12-16 US US13/132,996 patent/US8501799B2/en not_active Expired - Fee Related
  • 2008-12-16 EP EP12195560.3A patent/EP2567618B1/fr active Active
  • 2008-12-16 EP EP08875636A patent/EP2375905B1/fr active Active
  • 2008-12-16 AU AU2008365564A patent/AU2008365564B2/en active Active

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events